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a B S T r a c T
BACKGROUND: Recent evidence suggests that the “oldest old” patients might benefit of partial nephrectomy (PN), 
but decision-making for this subset of patients is still controversial. aim of this study is to compare outcomes of robotic 
partial (rPN) or radical nephrectomy (rrN) for large renal masses in patients older than 65 years.
METHODS: We identified 417≥65 years old patients who underwent RRN or RPN for cT1b or ≥cT2 renal mass at 17 
high volume centers. Propensity score match analysis was performed adjusting for age, ASA≥3, pre-operative eGFR, and 
clinical tumor size. Predictors of complications, functional and oncological outcomes were evaluated in multivariable 
logistic and cox regression models.
reSUlTS: after propensity score analysis, 73 patients in the rPN group were matched with 74 in the rrN group. 
r.e.N.a.l. Score (9.6±1.7 vs. 8.6±1.7; P<0.001), and high complexity (56 vs. 15%; P=0.001) were higher in the rrN. 
estimated blood loss was higher in the rPN group (200 vs. 100 ml; P<0.001). rPN showed higher rate of overall com-
plications (38 vs. 23%; P=0.05), but not major complications (P=0.678). at last follow-up, rPN group showed better 
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data for the present study were retrieved from a 
multi-institutional multinational database. over-
all, 417 patients 65 years or older who underwent 
RRN or RPN for cT1b or ≥cT2 renal mass were 
included.
Baseline patient characteristics (age at the 
surgery, gender, body mass index [BMi], aSa 
Score ≥3, diabetes, hypertension, chronic kidney 
disease ≥class III, preoperative Hb, and estimat-
ed glomerular filtration rate [eGFR], and soli-
tary kindey status), clinical staging (tumor size, 
r.e.N.a.l. Score [continuous and categorical], 
cT, cN+, cM+), surgical outcomes (transperito-
neal approach, operative time [oT], estimated 
blood loss [eBl], intraoperative transfusions, 
complications [intraoperative, overall, ≤30 days, 
major according to Clavien-Dindo classifica-
tion ≥3], length of stay [LoS], re-admission rate 
within 30 days, and Hb at discharge), pathologi-
cal outcomes (tumor size, benign histology, pT, 
pN+, Fuhrman grade ≥3, positive surgical mar-
gins [PSM]), functional outcomes (egfr and 
ΔeGFR at discharge, 6, 12, and last follow-up) 
recurrence free survival (rfS) and overall sur-
vival (oS) were assessed.
Statistical analysis
in order to account for any potential baseline dif-
ferences among the two groups, adjustment was 
performed using a 1:1 nearest-neighbor propen-
sity score-matching.14
Propensity scores were computed using a lo-
gistic regression model to account for all mea-
surable potential confounders. The quality of the 
matching was assessed through the pstest and ps-
graph commands. an acceptable matching qual-
ity was achieved: before matching B=94.6%, af-
ter matching B=22% (figure 1).
current urological guidelines recommend par-tial nephrectomy (PN) as the elective treat-
ment for cT1a renal masses, whereas radical ne-
phrectomy (rN) remains the primary option for 
cT1b and ≥cT2 tumors.1, 2 However, PN for large 
renal masses has begun to be considered a valid 
and safe treatment option in terms of oncological 
control, and improved functional outcomes also 
for larger renal masses.3 The widespread adoption 
of robotic surgery and its well-known technical 
advantages in terms of visualization and handling 
of the anatomical structures favored the use of 
robot-assisted PN (rPN) for large renal masses 
as well.4, 5 in addition, cardiovascular,6 and on-
cological outcomes7 indicate that PN could also 
be suitable for elderly patients, who are usually 
more likely to be elected to rN.8, 9 furthermore, 
recent evidence suggests that the “oldest old” 
patients might benefit of PN in terms of surgical 
functional outcomes, and oncological safety.10-13 
However, the rate of elderly patients who under-
went PN for large renal mass (cT1b or ≥cT2) in 
these studies was underrepresented. Moreover, 
available evidence on robotic radical nephrec-
tomy (rrN) in elderly patients is poor and scarce 
and without adequate comparison to rPN.
Therefore, the aim of this study was to assess 
the feasibility and safety of rPN in a large co-
hort of patients aged ≥65 with large renal masses 
and to compare the perioperative, functional, and 
intermediate-term oncological outcomes of rPN 
vs. rrN in this subset of patients, for whom de-
cision-making is still controversial.
Materials and methods
institutional review board approval and data 
sharing was obtained at each center involved. all 
functional outcomes both in egfr (55.4±22.6 vs. 45.7±15.7 ml/min; P=0.016) and lower egfr variation (9.7 vs. 23.0 
ml/min; P<0.001). The procedure type was not associated with recurrence free survival (rfS) (Hr: 0.47; P=0.152) and 
overall mortality (oM) (0.22; P=0.084).
coNclUSioNS: rPN in elderly patients with large renal masses provides acceptable surgical, and oncological out-
comes allowing better functional preservation relative to rrN. The decision to undergo rPN in this subset of patients 
should be tailored on a case by case basis.
(Cite this article as: Veccia a, Dell’oglio P, antonelli a, Minervini a, Simone g, challacombe B, et al. robotic partial 
nephrectomy versus radical nephrectomy in elderly patients with large renal masses. Minerva Urol Nefrol 2020;72:99-108. 
Doi: 10.23736/S0393-2249.19.03583-5)
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Stata Statistical Software: release 15. Statacorp 
llc, college Station, TX, USa), and statistical 
significance was set at P≤0.05.
Results
Baseline characteristics of study cohort before 
matching
Before matching 143 and 273 patients were 
found in the rrN and rPN, respectively. The 
baseline Hb level was higher in the rPN group: 
13.9 (12.5-15.1) vs. 12.8 (11.7-14.0) g/dl; 
P<0.001. The rPN group demonstrated smaller 
tumor size (7.0 vs. 8.1 cm; P<0.001), and lower 
r.e.N.a.l. Score (8.0 vs. 10.0; P<0.001) and 
fewer high complexity masses (30 vs. 58%; 
P<0.001). Patients undergoing rrN had a higher 
rate of clinically advanced disease (cT≥ 3: 13 vs. 
9%; P<0.001-cN+ 8 vs. 1%; P=0.004-cM+ 19 vs. 
3%; P<0.001).
Baseline characteristics of study cohort after 
matching
after propensity score analysis 73 patients in 
the rPN group were matched with 74 in the 
RRN one. No statistically significant difference 
was found in terms of baseline features and tu-
mor dimensions between rPN and rrN groups 
(P=0.685). However, the r.e.N.a.l. Score 
(9.6±1.7 vs. 8.6±1.7; P<0.001), and proportion of 
high-complexity tumors (56 vs. 15%; P=0.001) 
were higher in the rrN group compared to rPN.
Statistical analysis was conducted accord-
ing to guidelines15 and consisted in three steps. 
first, Shapiro-Wilk Test was used to establish 
the distribution of the data. Median (interquartile 
range [iQr]) was used to report not-parametric 
data, while mean ± standard deviation (SD) was 
adopted for parametric data. Proportions were 
used to report categorical data. To compare the 
differences in the distribution of continuous and 
categorical variables between cases treated with 
rPN and rrN, Mann-Whitney U-test and fish-
er’s exact were used, respectively. When contin-
uous variables showed parametric distribution, 
Student’s t-test was used.
Three separate sets of multivariable logistic 
and Cox regression models were fitted to evalu-
ate the effect of the type of procedure (rPN vs. 
rrN) on overall complications, egfr decrease 
≥25% (at discharge, 6 and 12 months, and at 
last follow-up), and rfS and oS. in multivari-
able models testing for overall complication, 
adjustment variables consisted of age, ASA≥ 3, 
r.e.N.a.l. Score, type of procedure (rPN vs. 
rrN), intraoperative transfusion, and intraop-
erative complications. in multivariable models 
testing for eGFR decrease ≥25%, adjustment 
variables were age, ASA≥3, preoperative eGFR, 
r.e.N.a.l. Score, and type of procedure (rPN 
vs. rrN). in multivariable models testing for 
recurrence and survival, adjustment variables 
consisted of r.e.N.a.l. Score and type of pro-
cedure (rPN vs. rrN). all statistical tests were 
performed with Stata® 15.0 (Statacorp 2017. 
figure 1.—Propensity score matching quality.
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Table I.— Patients’ baseline features and outcomes.
Before matching after matching
Variablesƒ rrN rPN P value rrN rPN P value
Number of patients 143 273 74 73
Baseline features
age (years) 72.0 (68.0-77.0) 72.0 (68.0-76.0) 0.308 71.3 (67.7-77.0) 73.0 (68.0-77.0) 0.388
gender (male) 95/143 (66%) 195/273 (71%) 0.313 50/74 (67%) 50/73 (68%) 1.000
BMi (kg/m2) 27.7 (24.5-30.2) 26.9 (24.6-30.0) 0.350 27.8 (24.8-31.0) 26.3 (24.3-30.3) 0.284
ASA ≥3 63/114 (55%) 107/226 (47%) 0.135 35/74 (47%) 38/73 (52%) 0.622
Diabetes 38/142 (27%) 63/242 (26%) 0.905 22/73 (30%) 24/69 (35%) 0.594
Hypertension 85/142 (60%) 126/242 (52%) 0.167 43/73 (59%) 34/69 (49%) 0.312
CKD≥III 16/141 (11%) 41/223 (18%) 0.077 11/72 (15%) 16/69 (23%) 0.286
Hb at baseline (g/dl) 12.8 (11.7-14.0) 13.9 (12.5-15.1) <0.001 13.0 (12.1-14.5) 13.6 (12.5-14.6) 0.111
egfr at baseline (ml/
min/1.73m2) ‡
64.5±20.2 67.4±22.0 0.216 65.8±17.4 66.1±23.3 0.939
Solitary kidney 1/121 (1%) 12/235 (5%) 0.069 1/74 (1%) 5/73 (7%) 0.116
clinical tumor staging
Tumor size (cm) 8.1 (7.2-9.8) 7.0 (5.0-8.0) <0.001 8.0 (7.1-9.0) 8.0 (7.3-8.6) 0.685
r.e.N.a.l. 
(continuous)
10.0 (9.0-11.0) 8.0 (7.0-10.0) <0.001 9.6±1.7‡ 8.6±1.7‡ <0.001
r.e.N.a.l. (complexity) <0.001 0.001
low (4-6) 4/122 (3%) 59/245 (24%) 3/68 (4%) 10/73 (14%)
intermediate (7-9) 47/122 (39%) 113/245 (46%) 27/68 (40%) 37/73 (51%)
High (10-12) 71/122 (58%) 73/245 (30%) 38/68 (56%) 11/73 (15%)
cT <0.001 0.222
1b 15/135 (11%) 143/272 (53%) 6/66 (9%) 10/73 (14%)
2a 74/135 (55%) 88/272 (32%) 41/66 (62%) 46/73 (63%)
2b 26/135 (19%) 16/272 (6%) 5/66 (8%) 9/73 (12%)
3a 17/135 (13%) 25/272 (9%) 12/66 (18%) 8/73 (11%)
3b 2/135 (1%) - 2/66 (3%) -
4 1/135 (1%) - - -
cN+ 12/143 (8%) 5/248 (1%) 0.004 5/74 (9%) 2/71 (3%) 0.442
cM+ 27/143 (19%) 7/264 (3%) <0.001 10/74 (13%) 3/73 (4%) 0.078
Surgical outcomes
Transperitoneal 119/123 (97%) 215/262 (82%) <0.001 69/70 (98%) 54/72 (75%) <0.001
oT (min) 174.0 (136.0-225.0) 160.0 (120.0-224.0) 0.049 160.0 (120.0-210.0) 158.0 (115.0-240.0) 0.872
eBl (ml) 100.0 (50.0-200.0) 150.0 (100.0-300.0) <0.001 100 (50.0-150.0) 200.0 (100.0-475.0) <0.001
intraoperative 
transfusions
6/143 (4%) 15/255 (6%) 0.614 1/74 (1%) 5/72 (7%) 0.114
intraoperative 
complications
10/100 (10%) 18/242 (7%) 0.277 3/67 (4%) 8/72 (11%) 0.211
overall complications 26/125 (20%) 58/243 (24%) 0.600 17/74 (23%) 28/73 (38%) 0.050
Major complications† 4/19 (21%) 9/47 (19%) 1.000 3/13 (23%) 4/24 (16%) 0.678
length of stay (days) 3.0 (2.0-4.0) 4.0 (3.0-6.0) <0.001 3.0 (2.0-5.5) 5.0 (4.0-7.0) <0.001
re-admission 30 days 7/107 (6%) 6/178 (3%) 0.227 4/66 (6%) 3/58 (5%) 1.000
Hb at discharge (g/dl) 11.4 (10.1-12.4) 10.9 (10.0-12.5) 0.470 11.5±1.5‡ 10.5±1.4‡ <0.001
Pathological outcomes
Tumor size (cm) 8.0 (6.5-9.9) 6.0 (4.8-7.8) <0.001 7.6±2.3‡ 7.2±1.9‡ 0.231
Benign tumor 5/143 (3%) 50/299 (17%) 0.044 5/74 (7%) 11/73 (15%) 0.120
pT≥3 72/143 (50%) 72/273 (26%) <0.001 40/74 (54%) 23/73 (31%) 0.008
pN+ 8/140 (6%) - <0.001 4/72 (5%) - <0.001
Fuhrman grade ≥3 70/124 (56%) 73/191 (38%) 0.001 32/64 (50%) 30/55 (54%) 0.046
PSM 11/142 (7%) 18/281 (6%) 0.539 10/70 (14%) 7/73 (9%) 0.445
functional outcomes
egfr at discharge 
(ml/min/1.73m2)
46.0 (37.0-56.9) 60.9 (41.6-71.7) <0.001 46.0 (37.5-58.6) 57.8 (38.9-70.3) 0.023
ΔeGFR at discharge
(ml/min/1.73m2)
12.5 (5.6-28.0) 10.1 (1.29-20.0) 0.027 15.2 (6.0-29.3) 10.9 (1.0-23.0) 0.084
egfr at 6 months (ml/
min/1.73m2)
46.0 (39.0-52.5) 52.1 (41.0-65.7) 0.050 46.0 (39.0-55.7) 51.9 (41.1-66.4) 0.201
ΔeGFR at 6 months
(ml/min/1.73m2)
19.0 (10.0-28.0) 10.9 (3.9-20.7) 0.006 19.0 (10.0-29.0) 11.5 (3.3-19.8) 0.032
egfr at 12 months 
(ml/min/1.73m2)
45.4 (42.0-58.7) 57.8 (39.9-70.6) 0.023 46.2 (42.0-59.0) 51.9 (34.0-66.4) 0.713
 (To be continued) 
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Histopathological and functional outcomes
The rrN group was found to have more ad-
vanced disease as evidenced by a higher rate 
of pT≥3 (54% vs. 31%; P=0.008). The rPN 
group demonstrated a higher egfr at discharge 
[57.8 (38.9-70.3) vs. 46.0 (37.5-58.6) ml/min; 
P=0.023]. at 6 months, egfr variation was 
lower in the rPN group [11.5 (3.3-19.8) vs. 19.0 
(10.0-29.0) ml/min; P=0.032]. at last follow-
up, the rPN group maintained a higher egfr 
(55.4±22.6 vs. 45.7±15.7 ml/min; P=0.016) and 
lower egfr variation (9.7 [0.7-19.9] vs. 23.0 
[11.0-31.0] ml/min; P<0.001). Median follow-
up was 19.5 (iQr: 8-40.5) months (Table i, fig-
ure 2). on multivariable logistic regression anal-
ysis, rPN reached the independent predictor sta-
tus for eGFR decrease ≥25% at discharge (OR: 
Surgical outcomes
regarding surgical outcomes, the transperi-
toneal approach was preferred with greater 
prevalence among the rrN group (98 vs. 75%; 
P<0.001). eBl was higher in the rPN group 
(200.0 [100.0-475.0] ml vs. 100 [50.0-150.0] 
ml; P<0.001), but no difference regarding intra-
operative transfusions were observed (P=0.114). 
Patients undergoing rPN had a higher rate of 
overall complications (38 vs. 23%; P=0.05), but 
there was no difference between groups for ma-
jor complications (P=0.678). rPN patients had 
longer loS (3.0 vs. 5.0 days; P<0.001) (Table i).
in multivariable logistic regression analysis, 
the type of the procedure did not reach the in-
dependent predictor status (or: 2.22; 95% ci: 
0.95, 5.19; P=0.064; Table ii).
Table I.— Patients’ baseline features and outcomes.
Before matching after matching
Variablesƒ rrN rPN P value rrN rPN P value
ΔeGFR at 12 months
(ml/min/1.73m2)
16.0 (6.7-27.0) 8.0 (1.2- 10.1) 0.203 16.0 (8.0-27.0) 12.4 (2.6-20.5) 0.262
egfr at last follow-up 
(ml/min/1.73m2)
46.0 (37.0-55.0) 61.0 (42.6-75.0) <0.001 45.7±15.7‡ 55.4±22.6‡ 0.016
ΔeGFR at last follow-up
(ml/min/1.73m2)
22.0 (11.0-29.7) 8.0 (1.2-18.1) <0.001 23.0 (11.0-31.0) 9.7 (0.7-19.9) <0.001
follow-up length 
(months)
14.5 (6.6-33.8) 22.0 (6.0-42.0) 0.139 12.0 (8.0-27.0) 30.0 (12.0-43.0) <0.001
eGFR≤45mL/
min/1.73m2 
at 6 months
30/61 (49%) 30/86 (35%) 0.059 25/51 (49%) 14/37 (38%) 0.385
eGFR≤45mL/
min/1.73m2 
at last follow-up
41/83 (49%) 48/167 (29%) 0.001 24/46 (50%) 20/55 (36%) 0.225
rrN: robotic radical nephrectomy; rPN: robotic partial nephrectomy; BMi: Body Mass index; cKD: chronic kidney disease; egfr: 
estimated glomerular filtration rate; OT: operative time; EBL: estimated blood loss; PSM: positive surgical margins.
†Clavien ≥3; ‡mean±standard deviation (SD); ƒmedian (interquartile range [iQr]), n/N (%).
 (continues).
Table II.— Logistic regression of predictors of overall complications.
Before matching after matching
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
Variables or 95% ci P value or 95% ci P value or 95% ci P value or 95% ci P value
age 0.96 0.92, 1.00 0.107 0.95 0.89, 1.00 0.086 0.97 0.91, 1.03 0.343 0.95 0.88, 1.01 0.155
ASA≥3 2.43 1.41, 4.18 0.001 3.44 1.83, 6.46 <0.001 2.74 1.31, 5.71 0.007 3.65 1.55, 8.59 0.003
r.e.N.a.l. Score 1.07 0.94, 1.22 0.263 1.07 0.91, 1.26 0.352 1.00 0.81, 1.23 0.979 1.00 0.95, 5.19 0.978
Type of procedure
rrN ref ref ref ref
rPN 1.19 0.70, 2.01 0.507 1.43 0.70, 2.91 0.316 2.08 1.01, 4.27 0.045 2.22 0.95, 5.19 0.064
intraoperative 
transfusions
1.31 0.45, 3.80 0.615 0.64 0.14, 2.83 0.560 1.16 0.20, 6.61 0.862 0.56 0.78, 4.02 0.566
intraoperative 
complications
1.62 0.63, 4.15 0.310 0.87 0.23, 3.25 0.897 1.40 0.38, 5.08 0.604 0.97 0.23, 4.06 0.975
RRN: robotic radical nephrectomy; RPN: robotic partial nephrectomy; OR: odds ratio; CI: Confidence Interval.
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Oncologic outcomes
Using multivariable cox regression analysis, the 
type of the procedure was not associated with 
rfS (Hr: 0.47; 95% ci: 0.17, 1.31; P=0.152; 
Table iV) and oM (0.22; 95% ci: 0.04, 1.21; 
P=0.084; Table iV). r.e.N.a.l. Score was found 
to be associated with shorter rfS (Hr: 1.40; 
95% ci: 1.02, 1.91; P=0.033; Table iV).
Discussion
To the best of our knowledge this study repre-
sents the largest report available to date on el-
derly patients treated with rPN for large renal 
masses, and the first one providing a compar-
ison between rPN and rrP in this subset of 
patients. our analysis revealed some interesting 
findings which may contribute to the debate on 
0.33; 95% ci: 0.15, 0.73; P=0.007), at 6 months 
(or: 0.23; 95% ci: 0.08, 0.67; P=0.007), and at 
last follow-up (or: 0.29; 95% ci: 0.12, 0.72; 
P=0.008; Table iii).
figure 2.—egfr values time distribution.
Table III.— Logistic regression of predictors of eGFR decrease ≥25%.
Before matching after matching
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
Variables or 95% ci P value or 95% ci P value or 95% ci P value or 95% ci P value
eGFR decrease≥25% at discharge
age 1.02 0.95, 1.04 0.931 1.02 0.96, 1.08 0.475 1.03 0.97, 1.09 0.328 1.03 0.96, 1.04 0.391
ASA≥3 0.90 0.54, 1.53 0.720 1.05 0.56, 2.00 0.858 0.81 0.41, 1.62 0.568 1.22 0.54, 2.75 0.625
Preoperative egfr 1.01 1.00, 1.03 0.003 1.02 1.00, 1.04 0.002 1.02 1.00, 1.04 0.004 1.03 1.01, 1.05 0.004
r.e.N.a.l. Score 1.10 0.96, 1.25 0.159 1.03 0.88, 1.21 0.677 1.03 0.83, 1.23 0.895 0.99 0.79, 1.25 0.998
Type of procedure
rN ref ref
PN 0.42 0.25, 0.70 0.001 0.26 0.14, 0.52 <0.001 0.42 0.20, 0.84 <0.001 0.33 0.15, 0.73 0.007
eGFR decrease≥25% at 6 months
age 1.00 0.94, 1.06 0.849 0.99 0.92, 1.06 0.856 1.00 0.93, 1.08 0.819 0.99 0.91, 1.07 0.833
ASA≥3 1.02 0.52, 2.02 0.933 1.33 0.58, 3.04 0.489 0.97 0.41, 2.26 0.953 1.06 0.38, 2.97 0.901
Pre-operative egfr 1.02 1.00, 1.04 0.007 1.03 1.00, 1.05 0.006 1.01 0.99, 1.04 0.094 1.02 0.99, 1.04 0.110
r.e.N.a.l. Score 0.99 0.83, 1.19 0.966 0.86 0.69, 1.07 0.203 0.98 0.76, 1.25 0.879 0.87 0.64, 1.17 0.367
Type of procedure
rN ref ref ref ref
PN 0.29 0.15, 0.59 0.001 0.21 0.09, 0.50 <0.001 0.27 0.11, 0.67 0.005 0.23 0.08, 0.67 0.007
eGFR decrease≥25% at 12 months
age 1.10 1.03, 1.19 0.005 1.11 1.02, 1.20 0.013 1.07 0.98, 1.17 0.111 1.06 0.97, 1.17 0.180
ASA≥3 1.29 0.61, 2.70 0.494 1.41 0.57, 3.46 0.447 1.23 0.48, 3.14 0.658 1.42 0.47, 4.28 0.526
Pre-operative egfr 1.01 0.99, 1.03 0.052 1.01 0.99, 1.04 0.095 1.01 0.99, 1.04 0.199 1.01 0.99, 1.04 0.281
r.e.N.a.l. Score 0.95 0.78, 1.17 0.684 0.90 0.71, 1.15 0.428 0.83 0.64, 1.09 0.201 0.83 0.61, 1.14 0.263
Type of procedure
rN ref ref ref ref
PN 0.45 0.21, 0.95 0.038 0.34 0.14, 0.86 0.024 0.77 0.30, 1.99 0.598 0.58 0.19, 1.77 0.344
eGFR decrease≥25% at last follow-up
age 1.04 0.99, 1.09 0.073 1.04 0.97, 1.10 0.205 1.02 0.95, 1.10 0.449 1.02 0.95, 1.10 0.477
ASA≥3 0.71 0.40, 1.25 0.241 0.70 0.34, 1.44 0.342 0.51 0.23, 1.14 0.105 0.64 0.24, 1.69 0.371
Pre-operative egfr 1.00 0.99, 1.02 0.188 1.00 0.99, 1.02 0.341 1.01 0.99, 1.03 0.240 1.00 0.98, 1.03 0.430
r.e.N.a.l. Score 1.21 1.04, 1.40 0.013 1.03 0.85, 1.24 0.747 0.97 0.77, 1.24 0.859 0.91 0.70, 1.18 0.495
Type of procedure
rN ref ref ref ref
PN 0.16 0.09, 0.29 <0.001 0.17 0.08, 0.36 <0.001 0.28 0.12, 0.64 0.003 0.29 0.12, 0.72 0.008
eGFR: estimated glomerular filtration rate; RN: radical nephrectomy; PN: partial nephrectomy; OR: odds ratio; CI: Confidence Interval.
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data there was no statistically significant differ-
ence in terms of intraoperative transfusions.
in our cohort we noticed a higher rate of 
overall complications in the rPN group, but no 
difference in major complications. This rate of 
complications is likely owed to the more com-
plex nature of the rPN procedure during which 
the risk is increased by the tumor resection and 
reconstructive phase. indeed, tumor excision 
might provoke pelvicalyceal system effraction, 
and vascular injury, especially during chal-
lenging procedures.18 our data showed that the 
only 4 major complications in the rPN group 
were 3 urine leakage that required ureteral stent 
placement, and 1 abdominal bleeding which 
was managed with endovascular embolization. 
In addition, we found that ASA Score≥3, but 
no surgical technique, was the only factor as-
sociated with the risk of overall complications. 
overall, our data suggest that rPN is feasible 
and potentially safe, but treatment decision be-
tween rPN and rrN must be balanced between 
outcomes, patients comorbidities, and quality 
of life which is more important than life expec-
tancy itself in elderly patients.19, 20 in addition, 
the higher rate of overall complications rate 
translated into longer loS in the rPN, another 
important factor to be considered in elderly pa-
tients.21
regarding pathological outcomes, patients 
undergoing rrN were found to have more ad-
vanced disease. This data is consistent with that 
of a recent report assessing outcomes of rN and 
PN within the reSUrge Project. in that study 
the authors assessed 1226 patients older than 75 
years and found higher rate of pT≥3 in those cases 
who underwent rN.12again, Venkatramani et 
al. assessed outcomes of rN and PN for cT1b-
cT2 within the National cancer Database. after 
propensity score analysis the authors matched 
nephron sparing surgery (NSS) for large (cT1b 
and cT2) tumors.
after propensity score analysis, we found no 
statistically significant difference in terms of 
baseline features, even for CKD≥ stage III and 
solitary kidney. This data mirrors previous litera-
ture regarding PN on rN performed for large re-
nal masses. Mir et al. described similar findings 
within a systematic review and meta-analysis of 
21 case-control studies on this topic.3 However, 
in our analysis we noticed a clinical trend to fa-
vor RPN over RRN in patients with CKD≥ stage 
iii (23% vs. 15%) or solitary kidney (7% vs. 1%). 
in addition, recent evidence that NSS might pro-
vide better cancer specific mortality may warrant 
consideration for large renal masses even in an 
elective setting.6, 16
contrary to previous reports, we found no 
statistically significant difference regarding 
clinical tumor size; however, rrN was mostly 
performed for complex tumors. given the me-
dian age of our cohort, one might argue that this 
could be consequence of the patients age, who 
are usually managed with rN than PN due to 
concerns of surgical complications.8 Neverthe-
less, NSS for large renal masses is challenging 
in every subset of patients, and tumor complex-
ity is one of the main factors considered during 
pre-operative planning. Despite this, NSS for 
high complexity tumors has shown to be fea-
sible in experienced hands. Indeed, Buffi et al. 
evaluated the outcomes of 255 patients who 
underwent rPN at tertiary referral centers in a 
multicenter design study and achieved optimal 
surgical outcomes in 158 (62%) patients.17 Their 
findings were consistent with ours, despite the 
lack of an elderly population. in fact, even if we 
found rPN to be associated with higher eBl, 
the difference with rrN was of only 100 ml 
which is clinically insignificant. To confirm this 
Table IV.— Cox regression of predictors of RFS and OM.
recurrence free survival overall survival
Variables Hr 95% ci P value Hr 95% ci P value
r.e.N.a.l. Score 1.40 1.02, 1.91 0.033 1.35 0.85, 2.14 0.194
Type of procedure
rN ref ref
PN 0.47 0.17, 1.31 0.152 0.22 0.04, 1.21 0.084
RN: radical nephrectomy; PN: partial nephrectomy; HR: hazard ratio; CI: Confidence Interval.
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associated to r.e.N.a.l. Score, whereas surgi-
cal procedure (rPN or rrN) was not found to 
be a predictor. This data corroborates those of 
previous studies assessing r.e.N.a.l. Score as 
predictor of malignancy, more advanced pathol-
ogy, and recurrence. Nagahara et al. demonstrat-
ed that high r.e.N.a.l. Score is associated with 
rfS (Hr: 9.05; P=0.0019).26
Limitations of the study
To the best of our knowledge this is the largest 
report describing the outcomes of elderly pa-
tients after rPN or rrN for large renal masses. 
This analysis is strengthened by the propensity 
score design and the sample size. Despite this, 
it is not devoid of limitations. first, the retro-
spective nature introduces biases which cannot 
be avoided. even if these were limited with the 
propensity score matched analysis, it presented 
a bias of 22%. Moreover, the aim to balance 
the two groups according to surgical technique 
reduced the numerosity of the two groups. a 
second important limitation is the absence of 
others fragility scores to assess patient’s perfor-
mance status and life expectancy. This analysis 
cannot be generalized to all clinical realities be-
cause all the procedures were performed in high 
volume centers with high proficiency in robotic 
and renal surgery. Kidney function was evalu-
ated through egfr which could be misleading 
because of the compensatory function of the 
contralateral kidney.27, 28 last, but not least, the 
follow-up period could be too short to evalu-
ate accurately survival outcomes. Moreover, 
the follow-up length was significantly longer in 
patients undergoing RRN. As such, our findings 
on oncological outcomes should be interpreted 
with caution. Notwithstanding these limita-
tions, this report provides further data regard-
ing the management of large renal masses even 
in elderly population.
Conclusions
rPN in elderly patients with large renal masses 
offers acceptable surgical, functional, and onco-
logical outcomes compared to rrN. The deci-
sion to undergo rPN in this subset of patients 
should be tailored on a case by case basis.
6072 patients per each group showing higher 
rate of pT≥3 in the RN group (13.1% vs. 6.9%; 
P<0.001).22 In our data the overall rate of pT≥3 
was higher for both groups (rPN 31% vs. rrN 
54%), but this difference could be explained by 
the different covariates selection to build the pro-
pensity model.
When comparing rPN and rrN, the func-
tional outcomes assessment deserves attention. 
rPN provided better kidney function compared 
to rrN, especially at medium and long-term fol-
low-up. indeed, the advantages of NSS surgery 
were not immediately obvious, whereas at last 
follow-up egfr and egfr variation were better 
for the rPN group. Nevertheless, the difference 
was of only about 10 ml/min and may not be 
clinically significant, but this could be the case 
in this subset of patients whose kidney function 
could be already impaired.23 of note, on multi-
variable analysis rPN showed a protective role 
regarding eGFR decrease ≥25%. These data mir-
ror literature evidence which largely assessed the 
functional advantages of nephrons unit preserva-
tion. a recent report compared function results of 
250 living donors and 118 partial nephrectomy 
patients. The authors evaluated % egfr varia-
tion at discharge, 1-7 months, and last follow-up, 
and achieved the conclusion that PN provided 
immediate better functional outcomes and that 
should be considered, even at expense of longer 
ischemia time.24 if this could be true for small 
renal masses, it might be different for large and 
complex ones. recently, Wu et al. conducted a 
refined analysis of the functional impact of the 
vascularized parenchymal mass preserved with 
partial nephrectomy and predictors. The authors 
identified four possible scenarios (1-4) based 
upon the percentage of parenchymal mass pre-
served after PN. The analysis demonstrated that 
high tumor complexity and dimension were re-
lated to suboptimal preservation of nephrons due 
to the larger resection and reconstruction. This 
could impair functional recovery despite NSS.25 
Given these findings, our study demonstrated 
rPN to provide better functional outcomes for 
large and complex renal masses in the subset of 
elderly patients, as already underlined in other 
reports.11, 12
Survival outcomes demonstrated rfS to be 
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